

Type 2 diabetes in adults: management

Economic modelling for continuous glucose
monitoring in adults with type 2 diabetes

NICE guideline NG28

Economic model report

March 2022

Final

*Developed by the Guideline Development
Team*

Disclaimer

Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer.

Copyright

© NICE 2022. All rights reserved. Subject to [Notice of rights](#).

ISBN: 978-1-4731-1477-7

Contents

HE1 Introduction	5
HE2 Methods	6
HE2.1 Model overview	6
HE2.1.1 Population(s).....	6
HE2.1.2 Interventions	6
HE2.1.3 Type of evaluation, time horizon, perspective, discount rate	6
HE2.2 Model structure.....	7
HE2.3 Parameters.....	7
HE2.3.1 Cohort parameters	8
HE2.3.2 Economics	11
HE2.3.3 Treatments.....	17
HE2.3.4 Clinical	20
HE2.3.5 Other management	20
HE2.4 Sensitivity analyses	21
HE2.4.1 Deterministic sensitivity analyses	21
HE2.4.2 Probabilistic sensitivity analyses	21
HE3 Results	23
HE3.1 Base-case cost–utility results	23
HE3.2 Deterministic sensitivity analysis.....	23
HE3.3 Probabilistic sensitivity analysis	24
HE3.4 Discussion	24
HE3.4.1 Principal findings.....	24
HE3.4.2 Weaknesses of the analysis.....	24
HE3.4.3 Comparison with other CUAs	25
HE3.5 Conclusions.....	25
HE4 References.....	26

HE1 Introduction

Given the costs and impact on health-related quality of life associated with hypoglycaemia and long-term complications of type 2 diabetes and unstable HbA1c control, the cost-effectiveness of real-time continuous glucose monitoring (rtCGM) and flash glucose monitoring (isCGM) versus conventional self-monitoring of blood glucose (SMBG) was identified by the guideline committee as an area of priority for economic analysis.

The review question addressed in this analysis is:

- In adults with type 2 diabetes, what is the most effective method of glucose monitoring to improve glycaemic control:
 - continuous glucose monitoring
 - flash glucose monitoring
 - conventional self-monitoring of blood glucose (also sometimes called intermittent capillary blood glucose monitoring)?

The decision problem this analysis is designed to address is summarised in Table HE001, with the full protocol for the clinical review available in appendix A of the evidence review for the guideline update.

In the economic literature review only one cost-utility analysis (CUA) was identified, looking at the cost-effectiveness of Freestyle Libre flash glucose monitoring to improve glycaemic control in adults with type 2 diabetes in the Scotland¹. The study found that flash appeared cost effective compared with SMBG in the base case and across a wide range of scenarios. However, the analysis was only based on a single RCT, rather than all the available clinical evidence, and no evidence was found for rtCGM, and therefore the committee agreed there was value in additional work being undertaken.

Table HE001: Health economic decision problem

Population	Adults (aged 18 years and older) with type 2 diabetes
Intervention	Method of glucose monitoring to improve glycaemic control: • real-time continuous glucose monitoring • flash glucose monitoring
Comparator	Conventional self-monitoring of blood glucose
Outcomes	Costs QALYs

HE2 Methods

HE2.1 Model overview

The previously published IQVIA CORE Diabetes model (CDM) version 9.5, which has been validated against clinical and epidemiological data, was used for the analysis. This was decided on due to the need for a model accounting for the long-term complications of diabetes within a lifetime time horizon, as agreed upon by the guideline committee. Given the complexity of modelling type 2 diabetes and the timeline constraints associated with this clinical guideline development, the committee agreed this was a more robust approach than attempting to develop a new model framework from scratch.

The CDM is a lifetime Markov simulation model predicting the progression of diabetes over time using a series of interlinked and interdependent Markov sub models for diabetes related complications. The model allows for transition probabilities and management strategies to be differentiated by type of diabetes. In our analysis, type 2 diabetes data was used where available.

In addition to reducing the occurrence of short-term complications such as hypoglycaemic events, automated glucose monitoring methods can also improve the stability of HbA1c levels, hence reducing long-term complications. Therefore, an economic analysis was undertaken to evaluate the cost-effectiveness of blood glucose monitoring methods, taking into account the benefits of lowering HbA1c levels and reducing severe and non-severe hypoglycaemic events. In addition, psychological benefits were also considered in the model as the technologies have a potential to enhance people's ability to manage their glucose levels and help them regain a sense of personal control over the condition.

HE2.1.1 Population(s)

The primary analysis looked at a cohort of adults representing average individuals with type 2 diabetes using insulin in the UK. Although some studies in the clinical review contained individual not using insulin, the committee agreed people using insulin were likely to be those who derived the most benefit from CGM, and therefore this was the baseline population modelled.

HE2.1.2 Interventions

The analysis simulates the following methods of glucose monitoring:

- real-time continuous glucose monitoring
- flash glucose monitoring
- conventional self-monitoring of blood glucose

Analyses of real-time continuous glucose monitoring versus self-monitoring of blood glucose, and flash glucose monitoring versus self-monitoring of blood glucose were conducted. The committee agreed an analysis of real-time versus flash monitoring would not be useful. This was because of the limited clinical data available for this comparison, and because the choice of device often depended on individual characteristics of the person, and therefore the average cost-effectiveness across the population may not be particularly useful.

HE2.1.3 Type of evaluation, time horizon, perspective, discount rate

A time horizon of 80 years was used in the base case since this was deemed sufficient to consider lifetime costs and outcomes (note that the IQVIA CDM model requires the number of years to be specified to define a time horizon). Costs and quality-adjusted life years (QALYs) were considered from a UK NHS perspective. The analysis follows the standard

assumptions of the NICE reference case including discounting at 3.5% for costs and health effects.

HE2.2 Model structure

The IQVIA CDM is a tool used to simulate disease progression in type 1 and type 2 diabetes patients over their lifetime. The type 2 diabetes version of the model has been previously validated² against epidemiological and clinical studies of type 2 diabetes. A more detailed description of IQVIA CDM has been published by Palmer et al³.

The IQVIA CDM can account for a range of interventions aimed at diabetes related complications. These include intensive or conventional insulin therapy, oral hypoglycaemic medications, screening and treatment strategies for microvascular complications, treatment strategy for end stage complications and multifactorial interventions.

Diabetes progression with the IQVIA CDM is simulated using a series of interlinked, inter-dependent sub-models which simulate the following complications:

- angina
- myocardial infarction
- congestive heart failure
- stroke
- peripheral vascular disease
- diabetic retinopathy
- macular oedema
- cataract
- hypoglycaemia
- ketoacidosis
- lactic acidosis
- nephropathy and end-stage renal disease
- neuropathy
- foot ulcer
- amputation
- non-specific mortality

The Markov sub models listed above use time, state, and diabetes type-dependent probabilities from published sources. Interactions between these sub models are moderated by employing Monte Carlo simulations using tracker variables⁴.

The IQVIA CDM was chosen for this analysis as it is a pre-validated model which accounts for long-term diabetes related complications across a time horizon extending to the lifetime of the patient.

HE2.3 Parameters

Model input parameters in the IQVIA CDM model are grouped under the following databases:

1. Cohort
2. Economics
 - Costs
 - Quality of life
3. Treatment
 - Treatment effects of insulin therapy
 - Treatment algorithm - a sequence of alternative treatments in the event a treatment is discontinued

- Treatment costs
4. Clinical
 5. Other Management

The default model input parameters for type 2 diabetes in the IQVIA CDM model were validated with the committee and, if found appropriate, were used. In a scenario where more reliable or recent UK specific sources were identified, these were used instead. Table HE002 to Table HE012 list the input parameters used in our analysis, with detail about the sources, calculations and rationale for selection listed in the sections below.

Where parameter values other than the IQVIA CDM default values were used, these were identified using the standard methods listed in the NICE guidelines manual. These include taking values from established routine national data sources, identifying relevant published studies through citation searching of the studies identified through the cost-effectiveness literature review, targeted literature searches, and through studies identified by committee members.

HE2.3.1 Cohort parameters

HE2.3.1.1 Baseline cohort characteristics

Within the IQVIA CDM model the baseline population needs to be defined in terms of patient's demographics, baseline risk factors, and pre-existing complications. These characteristics were sourced from a range of UK specific type 2 diabetes populations (and aimed to be representative of the population of people with type 2 diabetes using insulin in the UK). Characteristics not reported in these sources were either set at default IQVIA CDM or kept at 0 due to a lack of data representative of UK population values (this generally applies to proportions of people having suffered a previous event that would be likely to be uncommon in the age range of the starting population simulated). The baseline cohort characteristics used alongside their sources are listed in Table HE002.

A number of baseline characteristics listed below were sourced from the dataset from the Health Improvement Network (THIN) that included 3.7 million people from 427 UK GP practices. About 131,000 people with type 2 diabetes were selected from the THIN dataset using READ codes, and the baseline characteristics were drawn from people at the time of their first insulin therapy.

We have used these baseline characteristics to simulate a cohort of 1,000 patients using the IQVIA CDM. Note that for characteristics where the standard deviation was kept at 0, the mean values were kept static when patient cohort was simulated. The simulated patient cohort also does not take into account correlations between risk factors.

Table HE002: Baseline cohort characteristics

Baseline characteristic	Mean	SD	Source/ Comments
Patient demographics			
Age (years)	65.41	13.67	National Diabetes Audit 2019-20 ⁵ Type 2 Diabetes Report: age and duration of diabetes were calculated by obtaining weighted averages since they were reported for categories of patients, rather than as a single mean age.
Duration of Diabetes (years)	9	5.57	
	0.559	n/a	
Prop. Male			
Baseline risk factors			
HbA1c (%)	7.6	1.5	Baseline HbA1c (%) values as one of the current risk factors for people with second intensification taken from Table 20 of NICE guideline NG28; originally sourced from

Baseline characteristic	Mean	SD	Source/ Comments
			THIN data. Conversion to mmol/mol: mean 59.57mmol/mol.
Systolic blood pressure (mmHg)	133.1	15.7	THIN data ⁶ : blood pressure (mmHg) values for patients with first insulin therapy
Diastolic blood pressure (mmHg)	80	0	IQVIA CDM default value ⁷
Total Cholesterol (mg/dL)	168.34	38.22	Baseline total cholesterol values (mean 4.36mmol/l; SD 0.99mmol/l) as one of the current risk factors for people with second intensification taken from Table 20 of NICE guideline NG28; originally sourced from THIN data; converted to mg/dL.
High density cholesterol (mg/dL)	44.85	12.56	THIN data ⁶ : HDL values (mean: 1.16mmol/l; SD: 0.33mmol/l) for patients with first insulin therapy; converted to mg/dL.
Low density cholesterol (mg/dL)	91.00	36.21	THIN data ⁶ : LDL values (mean: 2.36mmol/l; SD: 0.94mmol/l) for patients with first insulin therapy; converted to mg/dL.
Triglyceride (mg/dL)	147.00	0	IQVIA CDM default value ⁷ ; Conversion to mmol/l: mean 1.66mmol/l
Body mass index (kg/m ²)	31.24	0.2	THIN data ⁶ : calculated from weight (kg) and height (m) values for patients with first insulin therapy
estimated glomerular filtration rate (ml/min/1.72m ²)	68.20	21.6	THIN data ⁶ : eGFR values for patients with first insulin therapy
Haemoglobin (gr/dl)	14.5	0	IQVIA CDM default value ⁸
White blood cell count (10 ⁶ /ml)	7.9	2.1	THIN data ⁶ : White blood cell count for patients with first insulin therapy
Heart rate (bpm)	72	0	IQVIA CDM default value ⁸
Waist to hip ratio	0.96	0.08	Health Survey for England 2017 & 2018 ⁹ – calculated from the subset of individuals with type 2 diabetes
Waist circumference	107.02	n/a	Health Survey for England 2017 & 2018 ⁹ – calculated from the subset of individuals with type 2 diabetes
Urinary Albumin creatinine ratio (mg/mmol)	3.10	0	IQVIA CDM default value ¹⁰
Serum Creatinine (mg/dL)	1.10	0	IQVIA CDM default value ¹⁰ ; ; Conversion to µmol/L: mean 97.24 µmol/l.
Serum Albumin (g/dl)	3.90	0	IQVIA CDM default value ¹⁰ ; Conversion to g/l: mean 39g/l.
Prop. Smoker	0.131	0	National Diabetes Audit 2019-20 ⁵ – calculated from the subset of individuals with type 2 diabetes
Cigarettes/ day	15	0	Health Survey for England 2017 & 2018 ⁹ – calculated from the subset of individuals with type 2 diabetes
Alcohol consumption (Oz/week)	7.70	0	WHO status report on alcohol 2018 ¹¹ (converted from l/year to oz/week)
Prop. Physical activity	0.612	0	Health Survey for England 2017 & 2018 ⁹ – calculated from the subset of individuals with type 2 diabetes

Baseline characteristic	Mean	SD	Source/ Comments
Fasting glucose	180.72	0	IQVIA CDM default value
Prop. Family history stroke	0.044	0	IQVIA CDM default value
Prop. Family history CHD	0.147	0	IQVIA CDM default value
Prop. China Northern region	n/a	n/a	n/a
Prop. China rural area	n/a	n/a	n/a
Racial characteristics			
Prop. White/ other	0.824	n/a	National Diabetes Audit 2019-20 ⁵ Type 1 Diabetes Report
Prop. Black	0.045	n/a	
Prop. Asian/ Pacific islander	0.131	n/a	
Baseline CVD complications			
Prop. MI	0.036	0	THIN data ⁶ : proportion of patients with first insulin therapy prior to time point when myocardial infarction occurred
Prop. Angina	0	0	IQVIA CDM default value ¹²
Prop. Peripheral vascular disease	0	0	Assumption
Prop. Stroke	0.017	0	THIN data ⁶ : proportion of patients with first insulin therapy prior to time point when stoke occurred
Prop. Heart failure	0.030	0	THIN data ⁶ : proportion of patients with first insulin therapy prior to time point when congestive heart failure occurred
Prop. Atrial Fibrillation	0	0	Assumption
Prop. Left venitucular hypertrophy	0	0	Assumption
Baseline renal complications			
Prop. Microalbuminuria (MA)	0.313	0	IQVIA CDM default value ⁷
Prop. Gross proternuria (GPR)	0.077	0	IQVIA CDM default value ⁷
Prop. End stage renal disease (ESRD)	0	0	Assumption
Baseline retinopathy complications			
Prop. Background retinopathy (BDR)	0.331	0	IQVIA CDM default value ¹³
Prop. Proliferative diabetic retinopathy (PDR)	0.071	0	IQVIA CDM default value ¹⁴
Prop. Severe vision loss (SVL)	0	0	Assumption
Baseline macular edema			
Prop. Macular Edema	0	n/a	Assumption
Baseline cataract			
Prop. Cataract	0	n/a	Assumption
Baseline foot ulcer complications			
Prop. History of ulcer	0	n/a	Assumption
Prop. History of amputation	0	n/a	Assumption
Baseline neuropathy			
Prop. Neuropathy	0.430	n/a	IQVIA CDM default value ¹⁵

HE2.3.1.2 Mortality

The IQVIA CDM offers four options to account for mortality within the model. These include the non-combined mortality approach where event and health state specific mortality are used to estimate fatal events (there is a lack of clarity about how non-event specific mortality is accounted for in this option), 2 UK specific approaches; the UKPDS 68 and UKPDS 82 approaches, and the Western Australia mortality approach where the data was sourced from an Australian population. Given that the UKPDS 68 and UKPDS 82 approaches were from UK specific populations, these were considered in more detail.

The UKPDS 68 approach uses 2 separate equations to predict the 1st and subsequent year mortality risks for diabetes related complications using information from the UKPDS population. This approach requires non-specific mortality risks stratified by ethnicity, gender, and age to be uploaded manually. However, given the unavailability of disease specific mortality (which is required to calculate non-specific mortality) by these stratifications for the relevant population in the UK, this approach was not used.

The UKPDS 82 approach uses four separate equations to estimate the incidence of death following “no history and no event”, “no history and event”, “history and no event”, and “history and event”. With it being clear that the excess mortality in the UKPDS 82 approach is reflective of a UK type 2 diabetes population due to it being sourced from the UKPDS, the UKPDS 82 approach was used.

HE2.3.2 Economics

HE2.3.2.1 Cost

Default values for costs of chronic and recurrent conditions, and complication costs in the IQVIA CDM model were updated to reflect those of contemporary clinical practice in the UK. Costs for medicines were taken from the NHS Drug Tariff, whilst costs associated with complications were sourced from other relevant NICE guidelines if available, or otherwise from either published papers or based on committee knowledge. No indirect costs were included in the analysis with these parameters set to 0 in the IQVIA CDM, as the indirect costs that can be included in the IQVIA CDM fall outside the NICE reference case.

The values used for resource use and costs are listed in Table HE003 with their relevant sources. All costs from earlier than 2019/20 were inflated to 2019/20 values using the Unit Costs of Health and Social Care 2019¹⁹. For the probabilistic analysis values were altered within a range of plus/minus 10%. Note that IQVIA CDM only allows for a single measure of variability across all cost parameters.

Table HE003: Management and complication costs

Input variables	Mean cost per year*	Source/ Comments
Management costs		
Statins	£27.38	Atorvastatin 80 mg tablets x 28 days (unit price: £2.10) - NHS Electronic Drug Tariff June 2021 ¹⁶
Aspirin	£16.43	Aspirin 75 mg tablets x 28 days (unit price: £1.26) - NHS Drug Electronic Tariff June 2021 ¹⁶
ACE-I/ARB	£22.84	Weighted (by use as reported by Prescription Cost Analysis data March 2021 ¹⁷) average costs of: ACE-I/ARB (Source: NHS Electronic Drug Tariff June 2021 ¹⁶) Enalapril (10mg x 28; Unit price: £7.04) Lisinopril (10mg tablets x 28; Unit price: £1.08)

Input variables	Mean cost per year*	Source/ Comments
		Perindopril arginine (10mg tablets x 30; Unit price: £10.65) Ramipril (10mg tablets x 30; Unit price: £1.42) Candesartan (8mg tablets x 28; Unit price: £1.54) Eprosartan (600mg tablets x 28; Unit price: £18.16) Losartan (50mg tabletsx 28; Unit price: £1.45) Telmisartan (40mg tablets x 28; Unit price: £2.69)
Screening for micro-albuminuria	£4.25	Cost of ACR/PCR testing from Kerr et al (2012) ¹⁸ who sourced patient numbers from Quality and Outcomes Framework (QOF) for General Practice and costs from PSSRU
Screening for gross proteinuria	£4.25	
Stopping ACE-I/ARB due to AEs	£39.23	Assumed as the cost of a GP visit as sourced from unit costs of health and social care 2020 ¹⁹
Eye Screening	£54.37	Local estimate provided via an ophthalmologist involved in the guideline on the 25 th of January 2021 (no published data were available for this parameter).
Annual cost of CVD complications		
MI 1st year	£4,076	NICE Cardiovascular disease risk guideline, CG181 The guideline calculates costs for management of CVD complications during the first 6 months for event states and 1-year post-event states. Costs calculated by using information from NHS Drug Tariff ¹² , procedure costs from NHS Reference costs, PSSRU Unit Costs of Health & Social Care ¹⁹ and the British National Formulary. Assumptions made: 1st year costs were assumed to be cost of first 6 months in event state plus half of 1-year post event state costs. 2nd year costs were assumed to be 1-year post-event state costs. Cost of stroke death within 30 days was assumed to be the cost of a cardiovascular death as reported in CG181. Assumed that one third of angina episodes are stable, and two thirds unstable, based on expert opinion in NG17. This assumption was validated by the committee, with no objections raised. Peripheral arterial disease (PAD) costs from CG181 assumed to be the same as PVD costs.
MI 2nd+ years	£861	
Angina 1st year	£6,999	
Angina 2nd+ years	£315	
CHF 1st year	£3,928	
CHF 2nd+ years	£2,837	
Stroke 1st year	£4,555	
Stroke 2nd+ years	£169	
stroke death within 30 days	£1,283	
PVD 1st year	£1,329	
PVD 2nd+ years	£578	
Renal Complications		
Haemodialysis 1st year	£33,579	Estimate sourced from 2021 update of the NICE chronic kidney disease guideline
Haemodialysis 2nd + years	£33,579	Estimate sourced from 2021 update of the NICE chronic kidney disease guideline
Peritoneal dialysis	£30,209	Estimate sourced from 2021 update of the NICE chronic kidney disease guideline
Peritoneal dialysis 2nd + years	£30,209	Estimate sourced from 2021 update of the NICE chronic kidney disease guideline
Renal transplant (1st year)	£21,012	Estimate sourced from 2021 update of the NICE chronic kidney disease guideline
Renal transplant (2nd year)	£8,332	Estimate sourced from 2021 update of the NICE chronic kidney disease guideline

Input variables	Mean cost per year*	Source/ Comments
Acute events		
Non-severe hypoglycaemic events	0	Information from Geelhoed et al ²⁰ shows that the costs associated with a non-severe hypoglycaemic event (NSHE) are minimal, with only 2.3% of patients experiencing a NSHE contacting a healthcare professional, and a NSHE only resulting in roughly 0.72 additional SMGB tests per week. Hence a cost of 0 was assumed.
Severe hypoglycaemic event	£370	Based on information from Hammer et al²¹ who reported results from 101 T1D patients in the UK. Here direct resource use costs included both in-hospital and outside of hospital (ambulance services, drugs administered, admission and care treatment, follow-up care, attendance by HCP) at the time of SHE and in follow-up (additional doctor visits, SMGB tests, further education in self-management). Unit costs were sourced from country specific and obtained from local health tariffs, formularies, and office for national statistics. The other potential source for hypoglycaemic was a study by Heller et al²² which reported resource use of severe hypoglycaemic events in 15 phase 3a trials. Given that this study only reported resource used (and not costs) a separate micro costing was needed to identify potential UK specific costs for ambulance, emergency room, non-medical assistance costs, etc. Given a lack of clarity about reliable sources for these costs we decided to use the data from Hammer et al, especially as the committee saw no significant limitations in the study by Hammer et al²¹. Although these costs were derived from a population of people with T1D, the committee agreed there was unlikely to be a significant difference in the cost of managing a hypoglycaemic event between people with T1D and T2D. Note: The IQVIA CDM offers inputs for a second class of severe hypoglycaemic events to account for severe hypoglycaemic events which required medical assistance (if it is decided to keep these separate from events not requiring medical assistance). However, as we have decided to keep severe hypoglycaemic events which required medical assistance and did not require medical assistance in the same category to match the way the cost data were reported, this was kept at 0.
Cost of eye disease		
Laser treatment	£145	NHS Reference Costs 2018/19 Currency code BZ86B - Non-surgical ophthalmology with interventions.
Cataract operation	£927	NHS Reference Costs 2018/19 Currency codes: BZ84A/BZ84B/BZ84C (Phacoemulsification Cataract Extraction and Lens Implant - CC Score 4+, 2-3, 0-1)
Following cataract operation	£203	NHS Reference Costs 2018/19

Input variables	Mean cost per year*	Source/ Comments
		Currency code: WF01A (Non-admitted face to face attendance, ophthalmology follow-up)
Blindness - year of onset	£7,570	NICE Glaucoma guideline, NG81
Blindness - following years	£7,314	Cost calculated by calculating costs of blind registration, low vision rehabilitation, community care, and residential care. These costs are then multiplied by the proportion of patients experiencing blindness who use these services. .
Cost of neuropathy/ foot-ulcer/ amputation		
Neuropathy 1st year	£37.10	Duloxetine (Zentiva) 60mg x 28 days priced at £2.77 (source: NHS Electronic Drug Tariff ¹⁶)
Neuropathy 2nd year onwards	£37.10	
Active ulcer	£3,520	Kerr et al (2019) ²³ - The cost of diabetic foot ulcers and amputations to the NHS in England. HES data (2014-15) used to calculate relevant inpatient activity, with costs of these activities calculated using reference costs.
Amputation event	£8,440	NICE Diabetic foot problems guideline, NG19 Amputation costs sourced from NHS reference costs. Amputation event costs calculated by combining amputations with and without major complications by using reported information on the probability an amputation is major.
Post amputation	£25,677	NICE Peripheral arterial disease guideline, CG147 Reported as the annual cost of care in subsequent years. Costs included: care home costs (£986/ week), community care costs (£296/ week), and wheelchair costs.

*Older costs have been inflated to current prices

HE2.3.2.2 Quality of life parameters

Quality of life parameters were set at default IQVIA CDM parameters values, except in the case of the impact on quality of life from severe and non-severe hypoglycaemic events (which were expected to be key drivers of the model).

Sources for impact of quality of life by severe and non-severe hypoglycaemic events were identified by looking at primary sources for quality-of-life parameters from our systematic review of economic evidence. The most commonly used sources in the literature were studies by Currie et al²⁴ and Evans et al²⁵.

Currie et al²⁴ sourced information from two surveys conducted in 2000 and 2004 among 1,305 respondents with diabetes. Impact on quality of life was measured using the EQ-5D instrument with the fear of hypoglycaemia measured using the Hypoglycaemia Fear Survey (HFS). Results were based on a multivariate analysis with pooled data used to explore the relationship between frequency of hypoglycaemic events and fear of hypoglycaemia (HFS values). Then the HFS values in conjunction with other independent variables was used to predict the EQ-5D values. Currie et al²⁴ reported results for severe, symptomatic, and nocturnal hypoglycaemic events with symptomatic events defined as mild or moderate event that did not require external assistance. However, the impact of QoL by nocturnal events were not reported by severity. Therefore, results from this study were not considered to fulfil all the desirable criteria for this analysis.

Evans et al²⁵ performed a web-based time trade-off (TTO) study where respondents are asked to “trade off” a portion of their remaining life span for an improved health state when compared to a hypothetical health state. 8,286 respondents were included from the UK, USA, Canada and Germany, which included 551 type 1 and 1,603 type 2 diabetes patients. Impact on QoL was reported for severe day time, severe nocturnal, non-severe daytime and non-severe nocturnal hypoglycaemic events, with results reported by country. Hence Evans et al reported information on all four categories of hypoglycaemic events required, and was therefore used in our analysis. The IQVIA CDM allows to account for diminishing non-severe hypoglycaemic utility (i.e. that the quality of life loss associated with having 2 non-severe hypoglycaemic events is less than twice the loss associated with 1 non-severe event) and for this information from Lauridson et al²⁶ was used as it was based on the same data set as Evans et al²⁵.

A direct utility benefit associated with using an isCGM device is included in the model, with the utility data derived from Matza et al²⁷, which aimed to quantify the ‘process utility’ associated with isCGM compared with SMBG (i.e. the direct quality of life benefits from using isCGM, based on people’s preferences for using the device, over and above the benefits from improved clinical outcomes such as HbA1c and hypoglycaemic events). In time trade-off interviews, the researchers asked general population participants in the United Kingdom (London and Edinburgh) to value health states that were drafted and refined on the basis of literature, clinician input and a pilot study. The health states had identical descriptions of diabetes and insulin treatment, differing only in glucose monitoring approach. This study showed a small but measurable utility benefit for isCGM. No similar study is available for continuous glucose monitoring. However, the committee were confident that the same ‘process utility’ benefits would occur for rtCGM as for isCGM, and felt it was reasonable to assume the same benefit to isCGM.

Table HE004: Quality of life values

Input variables	Mean utility	se	Source/ Comment
No complications	0.785	0.007	Default value in IQVIA CDM which was sourced from Beaudet et al ²⁹
Disutility of MI event	-0.055	0.005	Default value in IQVIA CDM which was sourced from a systematic review by Beaudet et al ²⁹ . Within this systematic review, these relevant parameters were sourced from Clarke et al ³⁰ . QoL post MI was assumed to be baseline utility minus disutility of MI from Beaudet et al ²⁹ . A similar calculation was done to obtain QoL post stroke and post amputation.
Utility post MI	0.73	0.009	
Utility CHF	0.6770	0.01	
Disutility of Stroke event	-0.164	0.008	
Utility post Stroke event	0.621	0.011	
Disutility amputation event	-0.280	0.011	
Utility post amputation	0.505	0.013	
Utility PVD	0.7240	0.008	Default value in IQVIA CDM which was sourced from a systematic review by Beaudet et al ²⁹ . Within this systematic review, these relevant parameters were sourced from Bagust et al ³¹
Utility gross proteinuria	0.7370	0.008	
Utility neuropathy	0.7010	0.008	
Disutility of ulcer	-0.1700	0.0189	Default value in IQVIA CDM which was sourced from a systematic review by Beaudet et al ²⁹ . Within this systematic review, these relevant parameters were sourced from Wasserfallen et al ³²
Utility haemodialysis	0.6210	0.029	
Utility peritoneal dialysis	0.5810	0.03	

Input variables	Mean utility	se	Source/ Comment
Utility background diabetic retinopathy (BDR)	0.7450	0.021	Default value in IQVIA CDM which was sourced from a systematic review by Beaudet et al ²⁹ . Within this systematic review, these relevant parameters were sourced from Fenwick et al ³³
Utility BDR wrongly treated	0.7450	0.022	
Utility macular edema	0.7450	0.021	
Utility renal transplant	0.7620	0.118	Default value in IQVIA CDM which was sourced from a systematic review by Beaudet et al ²⁹ . Within this systematic review, these relevant parameters were sourced from Kiberd et al ³⁴
Utility cataract	0.7690	0.016	Default value in IQVIA CDM which was sourced from a systematic review by Beaudet et al ²⁹ . Within this systematic review, these relevant parameters were sourced from Lee et al ³⁵
Utility proliferative diabetic retinopathy (PDR) laser treatment	0.7150	0.022	Default value in IQVIA CDM which was sourced from a systematic review by Beaudet et al ²⁹ .
Utility PDR no laser	0.7150	0.022	
Utility angina	0.6950	0.01	
Utility microalbuminuria	0.7850	0.007	
Disutility NSHE daytime	-0.005	0.00077	UK patients from a TTO survey in five countries (UK, USA, Canada, Germany & Sweden) from Evans et al ²⁵ . This study was based hypothetical health states, with the description of health states to all respondents (T1D, T2D and non-diabetic) being the same (meaning even people with T2D were not asked to report on how bad their own events are, but how bad it would be to suffer the hypothetical event described). It should be noted that this approach leads to larger estimates of QoL loss than when people are asked to rate their own events (mainly due to adaptation effects – people tend to get used to the events they suffer and so how bad they feel they are can reduce over time, even if the events themselves are just as bad). The descriptions of these health states were derived from a survey of 247 UK patients with diabetes. Hence given that all respondents answered the TTO survey based on the described hypothetical health states, no differences should be assumed between categories of patients. A more important distinction to make is that of results between specific countries, given the differences in the perception of a full health states between countries. Hence given that this analysis is done for a UK population, the UK specific value set was used. Note that the lower CI for NSHE nocturnal was reported as 0.06 which was assumed to be an error, and 0.006 was used when calculating the standard error
Disutility NSHE nocturnal	-0.008	0.00102	
Disutility SHE daytime	-0.062	0.00433	
Disutility SHE nocturnal	-0.066	0.00485	

Input variables	Mean utility	se	Source/ Comment
Disutility for 1 unit increase in BMI above 25 kg/m ²	-0.0061	n/a	Default value in IQVIA CDM - sourced from Bagust et al ³¹
Utility gain of using isCGM (direct utility benefit)	0.03	n/a	Matza et al ²⁷
Utility gain of using rtCGM (direct utility benefit)	0.03	n/a	Committee assumption

HE2.3.3 Treatments

HE2.3.3.1 Treatment effects of glucose monitoring devices

Treatment effects for the outcomes listed below were based on the meta-analyses performed as part of the clinical evidence review for this topic (see appendices F and G of the evidence review for the guideline update).

Reduction in HbA1c levels

The reduction in HbA1c levels, calculated as the mean change from baseline are listed in Table HE005. The mean change for SMBG was taken from the [economic modelling](#) undertaken for pharmacological management of type 2 diabetes, using the numbers estimated for Metformin-NPH insulin, as this was felt to be reasonably reflective of people at the time of their first insulin injection. The committee noted it was unlikely that the cost-effectiveness of different monitoring techniques would change considerably based on differences in the underlying insulin regimen used, as the benefits of rtCGM and isCGM would be expected to accrue for all insulin regimens.

The estimated differences between SMBG and rtCGM and isCGM were then applied to this baseline value for SMBG to estimate changes from baseline in HbA1c for rtCGM and isCGM. All studies with a follow-up of longer than three months were included as part of this calculation, regardless of whether the study participants were treated with insulin or not. Full details of the analyses from which these values were derived are given in appendix F and G of the guideline evidence review.

Table HE005: Reduction in HbA1c levels

Treatments	Change in HbA1c	Se	Source
rtCGM	-0.865	0.088	Clinical review
isCGM	-0.655	0.159	Clinical review
SMBG	-0.535	n/a	NG28: Metformin-NPH insulin

Severe hypoglycaemic events

The CORE diabetes model accounts for severe and non-severe hypoglycaemia using the hypoglycaemic event rates (per 100 patient years), and therefore we did not consider other hypoglycaemia-related clinical outcomes, such as the amount of time spent within a certain range of sensor glucose values. As for modelling HbA1c values, rates of severe hypoglycaemia for the SMBG arm of the model were taken from the [economic modelling](#) for pharmacological management of type 2 diabetes, using the numbers estimated for Metformin-NPH insulin. Due to a lower rate of severe hypoglycaemia among people with type 2 diabetes compared to type 1, both studies included in the clinical meta-analysis for rtCGM recorded no events in either the rtCGM or SMBG group^{36,37}. Therefore, we assumed no

difference in severe hypoglycaemic event rate across the study arms (although this assumption was tested in a sensitivity analysis).

Severe hypoglycaemic event rates for the isCGM arm were based on Haak et al³⁸, the only study included in the clinical review that reported the number of events related with hypoglycaemia below various glucose ranges. As a proxy for severe hypoglycaemia, an outcome of sensor glucose values <2.2mmol/L (40 mg/dL) per 24 hour period was used. The number of events per day reduced for both arms but the extent of reduction was greater for the isCGM group, representing a statistically significant ($p<0.0001$) 52.6% reduction in the time participants spent in this hypoglycaemic range compared with the SMBG group.

Severe hypoglycaemic event rates (per 100 patient years) used in the base-case analysis are listed in table HE006.

Table HE006: Severe hypoglycaemic event rates

Treatments	Event rate (per 100 patient years)
rtCGM	12.4487
isCGM	5.901
SMBG	12.4487

Non-severe hypoglycaemic events

As for modelling HbA1c and severe hypoglycaemia, rates of non-severe hypoglycaemia for the SMBG arm of the model were taken from the [economic modelling](#) for pharmacological management of type 2 diabetes, using the numbers estimated for Metformin-NPH insulin. Since no study was found in the clinical review that reported non-severe hypoglycaemic events for rtCGM, we assumed there is no difference between the rtCGM and the SMBG arm.

Non-severe hypoglycaemic event rates for the isCGM arm were based on Haak et al³⁸, the only study included in the clinical review that reported the number of events related with hypoglycaemia below various glucose ranges. As a proxy for severe hypoglycaemia, an outcome of sensor glucose values <3.9mmol/L (70 mg/dL) per 24 hour period was used. The number of events per day reduced for both arms but the extent of reduction was greater for the isCGM group, representing a statistically significant ($p<0.0001$) 27.7% reduction in the time participants spent in this hypoglycaemic range compared with the SMBG group.

Non-severe hypoglycaemic event rates (per 100 patient years) used in the base-case analysis are listed in table HE007.

Table HE007: Non-severe hypoglycaemic event rates

Treatments	Event rate (per 100 patient years)
rtCGM	1079.75
isCGM	780.66
SMBG	1079.75

Nocturnal hypoglycaemic events

The clinical evidence review found no strong evidence to suggest the proportion of nocturnal hypoglycaemic events differs based on the type of monitoring used. Thus, if a device reduces the number of hypoglycaemic events, it is likely to reduce both daytime and nocturnal events by approximately the same proportion, and therefore a single proportion of nocturnal events was applied across all the treatment arms. This proportion (13.96%) was taken from the [economic modelling](#) undertaken for comparing different insulin therapies for people with type 1 diabetes, using the numbers estimated for detemir twice daily insulin (the

committee agreed there was no reason to believe the proportion of nocturnal hypoglycaemic events in all hypoglycaemic events would systemically differ between type 1 and type 2 diabetes).

HE2.3.3.2 Treatment algorithm

The IQVIA CDM allows to define a treatment algorithm for each intervention in the event of treatment failure. Given the lack of evidence of differences between glucose monitoring methods with regard to the discontinuation of treatments, no treatment failure was assumed in this analysis.

HE2.3.3.3 Treatment costs

Monitoring device costs

We derived the cost for isCGM from NHS England's national arrangements³⁹, which outline the cost to the NHS of flash glucose monitoring. The cost of each sensor is £35 and each lasts two weeks. The annual cost is therefore $26 \times £35 = £910$.

For rtCGM, our base case assumes an annual cost of £2000. This is the ceiling price listed in the NHS England and NHS Improvement funding document (September 2020)⁴⁰. This ceiling price is only directly applicable for pregnant women, but the committee agreed that it was a reasonable proxy for the prices that may be paid for rtCGM for non-pregnant population as well, assuming rtCGM was widely rolled out for people with diabetes.

Table HE008: Annual costs of monitoring approaches

Treatments	Cost
isCGM	£910
rtCGM	£2,000

SMBG costs

In the absence of a glucose monitoring device, SMBG is the sole method used to determine blood glucose levels. When a device is used, some self-monitoring will still be required. The model estimates SMBG costs by multiplying the daily frequency of self-monitoring by the unit cost of strips and lancets (£0.26 combined). We obtained this cost from the average of all the strips and lancets reported as first-line diabetic equipment in the NHS Electronic Drug Tariff¹⁶.

We identified data regarding frequency of SMBG from previous literature among people with type 1 diabetes, shown in Table HE011. The committee advised that although the following numbers come from type 1 diabetes population, it is likely that they also broadly reflect the average frequency in SMBG use among people with type 2 diabetes who are using insulin. In case there are some variations across different types of diabetes, we account for the uncertainty in SMBG use in the sensitivity analyses described below.

Table HE009: SMBG resource use

Parameter name	Value	Source
Daily self-monitoring		
SMBG	4.6	Roze et al ⁴¹
isCGM	0.46	Healthcare Improvement Scotland ¹
rtCGM	0.15	Roze et al ⁴¹

HE2.3.4 Clinical

The clinical module with the IQVIA CDM contains data that describes the natural history of diseases. Default parameters for the type 2 diabetes were used in this module. The clinical parameters and the clinical progression parameters (transitional probabilities) used in the default version for type 2 diabetes patients are explained in more detail in the IQVIA CDM manual.

Whilst default parameters in the clinical module were used, decision relating to the clinical module were required to be made across other modules. Decisions to be made in the treatment module included choosing the progression equations for HbA1c, systolic blood pressure, diastolic blood pressure, total cholesterol, LDL, HDL, triglycerides, BMI, eGFR and waste to hip ratio in the treatment module (in our analysis the clinical database option which was the only to source information from a type 1 diabetes population was used), and risk adjustments for statins and ACE-I/ARB were used (selected option “yes”).

HE2.3.5 Other management

Table HE012 lists the input parameters used for proportions of patients who were managed for various chronic and recurrent conditions.

Table HE010: Other management parameters

Input parameter	Mean	Source/ comments
Concomitant medications		
Proportion on aspirin for primary prevention	0.59	Sourced from EUROASPIRE II Study group and Kotseva et al
Proportion on statins for primary prevention	0.474	
Proportion on ACE-inhibitors for primary prevention	0.213	
Proportion on aspirin for secondary prevention	0.887	Sourced from Kotseva et al
Proportion on statins for secondary prevention	0.841	
Proportion on ACE-inhibitors for secondary prevention	0.755	
Screening and patient management proportions		
Proportion screened for eye disease	1.00	No UK data, assumed to be standard management, in line with the UK diabetes eye screening programme
Proportion screened for renal disease	1.00	Assumed as recommended by NICE CG66, and should reflect current practice
Proportion receiving intensive insulin after MI	1.00	Sourced from Bydureon NICE TA submission
Others		
Sensitivity of eye screening	80%	Sourced from Lopes-Bastida 2007
Specificity of eye screening	97%	
Sensitivity of gross proteinuria screening	85%	
Sensitivity of micro albuminuria screening	75%	Sourced from Cortes-Sanabria 2006

Input parameter	Mean	Source/ comments
Specificity of micro albuminuria screening	97%	

HE2.4 Sensitivity analyses

No evidence was identified from the clinical review suggesting differences in treatment effectiveness in different patient subgroups (for example by ethnicity or age) and therefore no sensitivity analyses were conducted looking at these subpopulations.

HE2.4.1 Deterministic sensitivity analyses

A number of deterministic sensitivity analyses were performed to test for the robustness of our base case results. These include:

- Diabetes duration:**
 Duration of diabetes was set to 0 to mimic a type 2 diabetes population at initial diagnosis. Information with regard to age, gender, ethnicity and proportion of smokers in a type 2 diabetes population at initial diagnosis was obtained from the National diabetes audit.
- Time horizon:**
 Reducing the time horizon on the analysis from lifetime (80 years) to 1 year and 10 years.
- HbA1c progression approach:**
 In the base analyses, it was assumed that the difference in HbA1c levels between rtCGM/isCGM and SMBG arms remained constant over time. In sensitivity analyses, the UKPDS progression approach was adopted, assuming that the difference in HbA1c between study arms reduced over time.
- Higher daily usage of SMBG**
 A higher frequency of SMBG (10 times per day) was assumed for both the SMBG arm (10 times per day) and rtCGM/isCGM arms (3 times per day) to represent a subgroup of people who use a substantial amount of SMBG, even when using other monitoring devices (for example, people who continue to test at meal times).
- Assume rtCGM is as effective as isCGM in reducing severe and non-severe hypoglycaemic events**
 The committee noted that it is unlikely that isCGM is more effective in reducing SHE and NSHE events than rtCGM. Given the lack of clinical evidence in the rtCGM arm, we adopted the treatment effectiveness data on severe and non-severe hypoglycaemia from isCGM and applied them to rtCGM.
- Lower annual cost of rtCGM**
 Based on discussions with the committee and providers, the annual cost was lowered to £1,600 per year to represent a potential price decrease in the future with widespread use of rt-CGM across NHS England.

HE2.4.2 Probabilistic sensitivity analyses

The IQVIA CDM allows for a probabilistic analysis to account for the uncertainty surrounding the model input parameters listed above. The probability distributions around each parameter

are set by default in the IQVIA CDM, as explained in the document available in the IQVIA CDM website. When the probabilistic version of the model is run, values are randomly selected simultaneously for each model input parameter from its respective probability distribution. These values are then used to calculate the respective costs and QALYs. This was repeated 1000 times (1000 bootstraps) for the base case, and then mean costs and QALYs calculated across those samples.

The following variables were left deterministic, due to the IQVIA CDM not accounting for uncertainty surrounding them:

- Costs of monitoring devices
- The cost-effectiveness threshold (defined as fixed by NICE)

Note that the deterministic version of IQVIA CDM also has an element of stochastic variability in it due to a baseline cohort of 1000 patients being simulated to run the economic analysis on.

HE3 Results

HE3.1 Base-case cost–utility results

The base case results (table HE013) showed that isCGM was cost-effective compared with SMBG at a threshold of £20,000 per QALY, while rtCGM was not cost-effective even if we increased the threshold to £30,000 per QALY.

Table HE011: Base-case deterministic cost–utility results

Treatments	Absolute		Incremental		
	Costs (£)	QALYs	Costs (£)	QALYs	ICER (vs SMBG)
SMBG	16,046	7.407			
rtCGM	34,056	7.800	18,010	0.393	45,791
isCGM	21,635	7.871	5,589	0.464	12,042

HE3.2 Deterministic sensitivity analysis

Most of the sensitivity analyses were only conducted for isCGM compared with SMBG since it was unnecessary to test the robustness of the results for rtCGM when it was clearly not a cost-effective treatment option in the base case analysis. The only sensitivity analysis for rtCGM is to assume that it has the same effect in reducing severe and non-severe hypoglycaemic events as the isCGM. Results of the sensitivity analyses performed are shown in Tables HE012 and HE013. isCGM remained cost-effective at a threshold of £20,000 per QALY across all scenarios. When assuming rtCGM has the same effect in reducing severe and non-severe hypoglycaemia as isCGM and lowering the annual cost of rtCGM, its ICERs decrease but still remain above £30,000 per QALY.

Table HE014: Summary findings of deterministic sensitivity analyses (isCGM vs. SMBG)

Sensitivity analyses	Costs		QALYs		ICER (vs SMBG)
	Flash	SMBG	isCGM	SMBG	
New onset diabetes	26,626	20,300	9.178	8.657	12,149
Time horizon 1 year	1,325	852	0.688	0.652	12,932
Time horizon 10 year	11,698	8,072	5.189	4.9	12,556
HbA1c progression UKPDS approach	21,932	16,300	7.848	7.404	12,673
Higher SMBG use	24,451	22,020	7.871	7.407	5,239

Table HE015: Summary findings of deterministic sensitivity analyses (rtCGM vs. SMBG)

Sensitivity analyses	Costs		QALYs		ICER (vs SMBG)
	rtCGM	SMBG	rtCGM	SMBG	
Same effectiveness as isCGM	33,767	16,046	7.891	7.407	36,584
Lower annual cost for rtCGM: £1,600	29,376	16,046	7.800	7.407	33,892


HE3.3 Probabilistic sensitivity analysis

Probabilistic sensitivity results were reported below in tables HE016, and the cost-effectiveness acceptability curves (CEAC) are shown in figure HE001. The probability of isCGM being cost-effective is about 65% at a threshold of £20,000 per QALY. As the threshold value increases, the probability also increases. However, the maximum value is around 80%, indicating that there is much uncertainty around our results.

Table HE017: Summary findings of probabilistic sensitivity analyses (isCGM vs. SMBG)

Sensitivity analyses	Costs		QALYs		ICER (vs SMBG)
	IsCGM	SMBG	IsCGM	SMBG	
Probabilistic sensitivity analyses	24,499	19,367	7.505	7.086	12,240

Figure HE002: Cost-effectiveness acceptability curve in probabilistic sensitivity analyses



HE3.4 Discussion

HE3.4.1 Principal findings

In the base analysis, isCGM was cost-effective compared with SMBG at a threshold of £20,000 per QALY. This held across all sensitivity analyses. However, the ICER of rtCGM exceeded £30,000 per QALY, even when we assumed that it had the same effectiveness as isCGM in reducing severe and non-severe hypoglycaemia. Notice that the effectiveness data for isCGM were based on one single study for adults who were on insulin treatments, and therefore the results were only directly applicable to insulin-treated type 2 diabetes population in the UK.

HE3.4.2 Weaknesses of the analysis

As common with economic analysis of this nature, there was uncertainty around the model input parameters. Therefore, a number of deterministic and probabilistic sensitivity analyses

were conducted along with two versions of base case scenarios, and isCGM remained cost-effective across all scenarios.

In our analysis the baseline factors were sourced from various UK specific sources. However, the lack of a single data source to obtain all baseline risk factors meant that covariances between baseline risk factors could not be accounted for. This particularly hampered our sensitivity analysis among newly diagnosed diabetes people where in an ideal situation all associated baseline risk factors would have changed through associated covariances once the baseline risk factor specific to this subgroup was changed.

HE3.4.3 Comparison with other CUAs

The literature review of economic evidence identified only one CUA in the context of the UK from Healthcare Improvement Scotland¹, which assessed the cost effectiveness of isCGM compared with SMBG. There were a number of differences between our study and this Scottish study. First, the Scottish study used a simple two-stage model structure that consisted of alive and death. Second, it only accounted for hypoglycaemic events and did not consider HbA1c levels as a health outcome in the model. Despite these differences in modelling structure and types of health outcomes, our results were consistent with this study that showed isCGM is cost effective compared with SMBG for people with type 2 diabetes.

HE3.5 Conclusions

Our economic analysis was based on information from the systematic review of current clinical evidence and a range of other model input parameters including costs and quality of life which were sourced following input from the committee. A number of deterministic and probabilistic sensitivity analyses were considered to account for uncertainty surrounding the model inputs.

Given the current clinical evidence, rtCGM did not seem to be a cost-effective option for people with type 2 diabetes. isCGM appeared to be cost-effective compared with SMBG at a threshold of £20,000 per QALY, and the results remained robust across all sensitivity analyses. However, notice that the cost-effectiveness of isCGM may only be applicable to insulin-treated type 2 diabetes population in the UK.

HE4 References

1. Healthcare Improvement Scotland. "What is the clinical and cost effectiveness of Freestyle Libre flash glucose monitoring for patients with diabetes mellitus treated with intensive insulin therapy? What is an evidence note?". SHTG Advice on health technologies: In response to an enquiry from the Scottish Diabetes Group (SDG). 2018.
2. McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE diabetes model. *Value Health* 2014;17(6):714-724.
3. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. *Current Medical Research and Opinion*. 2004;20(sup1):S5-S26.
4. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. *Current Medical Research and Opinion*. 2004;20(sup1):S5-S26.
5. NHS Digital. National Diabetes Audit (NDA) 2019-20 Type 1 Diabetes report – Supporting Information. Published online 12th August 2021. <https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-2019-20-type-1-diabetes>.
6. NHS Digital. Type II Diabetes Analysis: Analysis of demographics, risk factors and complications using the The Health Improvement Network (THIN) database. Accessed March 2021.
7. The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. *New England Journal of Medicine* 2009; 362:1575-1585.
8. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. *Diabetologia* 2013; 56(9):1925-33.
9. NHS Digital. Health Survey for England 2017 & 2018. Published online 4th December 2018 & 3rd December 2019. <https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england>
10. Aaron R, Folsom et al. Prediction of Coronary Heart Disease in Middle-Aged Adults With Diabetes. *Diabetes Care* 2003; 26(10): 2777–2784.
11. World Health Organisation. Global status report on alcohol and health 2018. Published online 2018. <https://apps.who.int/iris/bitstream/handle/10665/274603/9789241565639-eng.pdf?ua=1&ua=1>
12. The ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods. *American Journal of Cardiology* 2007;99[suppl]:21i-33i
13. Stolk RP, van Schooneveld MJ, Cruickshank JK, et al. Retinal vascular lesions in patients of Caucasian and Asian origin with type 2 diabetes: baseline results from the ADVANCE Retinal Measurements (AdRem) study. *Diabetes Care* 2008;31(4):708-13.
14. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine* 2008;358:2560-72.
15. Ismail-Beigi F et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* 2010;376:419-430
16. National Health Service. Electronic Drug Tariff. Published 2021. Accessed June 22, 2021. <https://www.drugtariff.nhsbsa.nhs.uk/#/00157519-FA/FA00157076/>

17. National Health Service. Prescription Cost Analysis (PCA) data March 2021. Published online 2021. <https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/prescription-cost-analysis-pca-data>
18. Kerr M, Bray B, Medcalf J, O'Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. *Nephrology Dialysis Transplant*. 2012;27(suppl_3):iii73-iii80.
19. Personal Social Services Research Unit. Unit Costs of Health and Social Care 2020. Published online 2020. <https://www.pssru.ac.uk/project-pages/unit-costs/>
20. Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, Lahtela J, Jensen MM, Östenson C-G. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. *Journal of Medical Economics*. 2013;16(12):1453-1461.
21. Hammer M, Lammert M, Mejías SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. *J Med Econ*. 2009;12(4):281-290.
22. Heller SR, Frier BM, Hersløv ML, Gundgaard J, Gough SCL. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. *Diabet Med*. 2016;33(4):471-477.
23. Kerr M, Barron E, Chadwick P, et al. The cost of diabetic foot ulcers and amputations to the National Health Service in England. *Diabet Med*. 2019;36(8):995-1002.
24. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. *Curr Med Res Opin*. 2006;22(8):1523-1534.
25. Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. *Health Qual Life Outcomes*. 2013;11(1):90.
26. Lauridsen JT, Lønborg J, Gundgaard J, Jensen HH. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries. *Quality Life Research*. 2014;23(9):2645-2650.
27. Matza, L. S., Stewart, K. D., Davies, E. W., Hellmund, R., Polonsky, W. H., & Kerr, D.. Health State Utilities Associated with Glucose Monitoring Devices. *Value in Health*. 2017;20(3):507-511.
28. Currie, C. J., Morgan, C. L., Poole, C. D., Sharplin, P., Lammert, M., & McEwan, P.. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. *Current Medical Research and Opinion*. 2006;22(8):1523-1534.
29. Beaudet A, Clegg J, Thuresson P-O, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes. *Value in Health*. 2014;17(4):462-470.
30. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). *Medical Decision Making*. 2002;22(4):340-349.
31. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. *Health Economics*. 2005;14(3):217-230.
32. Wasserfallen J-B, Halabi G, Saudan P, et al. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. *Nephrology Dialysis Transplant*. 2004;19(6):1594-1599.
33. Fenwick EK, Xie J, Ratcliffe J, et al. The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. *Investigative Ophthalmology & Visual Science*. 2012;53(2):677-684.
34. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. *BMJ*. 1995;311(7020):1595-1599.
35. Lee WJ, Song K-H, Noh JH, Choi YJ, Jo M-W. Health-related quality of life using the EuroQol 5D questionnaire in Korean patients with type 2 diabetes. *Journal of Korean Medical Science*. 2012;27(3):255-260.
36. Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. *JAMA*.

- 2017;317(4):371-8.
37. Tildesley HD, Wright AM, Chan JH, Mazanderani AB, Ross SA, Tildesley HG, et al. A comparison of internet monitoring with continuous glucose monitoring in insulin-requiring type 2 diabetes mellitus. *Canadian Journal of Diabetes*. 2013;37(5):305-8.
 38. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J-P, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. *Diabetes Therapy*. 2017;8(1):55-73.
 39. NHS England. Flash glucose monitoring: national arrangements for funding of relevant diabetes patients. 2019. Available from: www.england.nhs.uk/publication/flash-glucose-monitoring-national-arrangements-for-funding-of-relevant-diabetes-patients
 40. NHS England and NHS Improvement. Type 2 Diabetes Prevention Programme and Type 1 diabetes glucose monitoring: Continuous glucose monitors – pregnancy. 2020. Available from: <https://www.england.nhs.uk/wp-content/uploads/2020/10/C0770-dpp-and-cgm-letter.pdf>.
 41. Roze, S., et al. "Long-term cost-effectiveness of dexcom G6 real-time continuous glucose monitoring versus self-monitoring of blood glucose in patients with type 1 diabetes in the U.K." *Diabetes care* 2020; 43(10): 2411-2417.